一、医疗器械注册证的具体情况 产品名称：一次性使用多通道单孔腹腔镜穿刺器 型号、规格：PDA-60-201、PDA-60-301、PDA-60-202、PDA-60-103、 PDA-80-201、PDA-80-301、PDA-80-202、PDA-80-103、PDB-60-220、 PDB-60-202、PDC-35-120、PDC-35-210、PDC-35-102、PDC-35-201 注册证编号：浙械注准20252021581 批准日期：2025年8月8日 证券代码：300314 证券简称：戴维医疗 公告编号：2025-039 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司于近日收到浙江省药品监督管理局颁发的1 项《医疗器械注册证》，具体如下： 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提 高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 四、风险提示 目前尚无法预 ...

Group 1 - The brain-computer interface (BCI) concept stocks have been active, with multiple stocks rising significantly, and several exceeding 100% increase in price year-to-date [1][3][4] - A recent policy document issued by seven government departments aims to accelerate the BCI industry's development, proposing 17 specific measures to enhance hardware and software capabilities, application of technological achievements, and support for innovation [2][4] - The document outlines a roadmap for BCI development, with milestones set for 2025 and 2027, including the establishment of a comprehensive support system and the cultivation of leading enterprises [5][6] Group 2 - The policy encourages various application scenarios, including industrial manufacturing, healthcare, and consumer applications, aiming to break down departmental barriers and enhance collaboration across the industry [7][8] - The BCI industry is transitioning from research to commercialization, with significant advancements in non-invasive technologies and ongoing efforts to develop core components domestically [8][9] - The medical sector is identified as the fastest-growing area for BCI commercialization, with a projected global market size of $40 billion by 2030, driven by the treatment of central nervous system diseases [9][10] Group 3 - Recent developments include the establishment of pricing for BCI medical services, with specific costs outlined for invasive and non-invasive procedures, providing a foundation for clinical application [12][13] - Several listed companies are actively engaging in the BCI sector, with ongoing research and product development in invasive and semi-invasive BCI applications [13][15] - Companies are also preparing to establish funds and partnerships to support innovation and investment in the BCI field, indicating a strong interest in the sector's growth [14][15]

Core Viewpoint - David Medical's stock price increased by 10.03% to 15.25 yuan, with a rolling PE ratio of 105.26, marking a new low in 388 days, and a total market value of 4.392 billion yuan [1] Company Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year, with a gross profit margin of 57.13% [2] Industry Comparison - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing David Medical at 105th in the industry ranking [1][2] - Other companies in the industry have varying PE ratios, with the lowest being 11.28 for Ji'an Medical and the highest being 20.81 for Sanxin Medical [2] Capital Flow - On August 11, David Medical saw a net inflow of 55.05 million yuan in main funds, with a total inflow of 32.57 million yuan over the past five days [1] Company Recognition - David Medical has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" and has received multiple honors, including "Zhejiang Province Well-Known Trademark" and "AAA Credit Rating Enterprise" [1]

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...

Group 1 - The brain-computer interface sector experienced a significant increase of 3.02% on August 11 [1] - Among the constituent stocks, Sainuo Medical reached the daily limit increase [1] - David Medical rose by 11.98%, Optoelectronic Co. increased by 7.27%, Innovative Medical grew by 6.53%, and Kunlun Wanwei saw a rise of 4.93% [1]

证券日报网讯戴维医疗（300314）8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总户数约为23900户。 ...

从8月5日公开信息显示，戴维医疗截至2025年7月31日公司股东户数为2.39万户，较上期（2025年7月18日）增加4900户，增 幅为25.79%，持股趋于分散。 从数据对比来看，戴维医疗户均持股数从上期1.52万股下降至本期1.21万股，户均持股市值从上期19.81万元下降至本期17.12 万元。上述区间，戴维医疗股价累计上涨7.48%。 截至发稿，戴维医疗报13.93元，下跌1.28%，市值40.12亿元。 最新5个统计日期，戴维医疗股东户数变动如下： 统计日期股东户数户均持股数（万股）户均持股市值（万元） 2025/07/31239001.2117.122025/07/18190001.5219.812025/07/10191001.5119.232025/06/10198001.4518.752025/05/30199001.4518.03 来源：金融界 ...

Group 1 - The stock price of David Medical reached 14.11 yuan as of August 4, 2025, with an increase of 0.03 yuan from the previous trading day [1] - The company operates in the medical device sector, focusing on the research and manufacturing of infant care equipment, including incubators and radiant warmers for newborns [1] - The latest data indicates a total market capitalization of 4.064 billion yuan and a price-to-earnings ratio of 45.02 [1] Group 2 - The HLD series medical isolation pad, referred to as the "baby nest," provides tactile stimulation and a sense of security for infants, effectively regulating heart rate, respiratory rate, and improving sleep quality [1] - On August 4, there was a net outflow of 22.0897 million yuan in main funds, accounting for 1.09% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 18.7868 million yuan, representing 0.93% of the circulating market value [1]

每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好，我发现公司有个婴儿鸟巢项目被 人比喻为人工子宫，请问具体是什么作用？ 戴维医疗（300314.SZ）8月4日在投资者互动平台表示，您所说的"婴儿鸟巢"即公司产品HLD系列医用 隔离垫，主要用于对病人提供一般性防护，以免受其他器械或外界的伤害，是一种可以给婴儿提供类似 子宫的触觉刺激和安全感的"鸟巢式"襁褓，能有效减慢婴儿心率、呼吸频率，延长睡眠时间，提高睡眠 质量。 （记者 张明双） ...

Group 1 - The core viewpoint of the news highlights the financial performance and stock market activity of David Medical (戴维医疗), indicating a decline in revenue and profit for the first quarter of 2025 [1] - As of August 1, 2025, David Medical's stock closed at 14.08 yuan, down 0.91%, with a turnover rate of 11.45% and a trading volume of 164,500 hands, amounting to a transaction value of 234 million yuan [1] - The company's latest quarterly report shows total operating revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit attributable to shareholders of 22.57 million yuan, down 40.78% year-on-year [1] Group 2 - The company has a current ratio of 4.798, a quick ratio of 3.738, and a debt-to-asset ratio of 13.99%, indicating a strong liquidity position [1] - David Medical has made investments in 6 companies and participated in 1,465 bidding projects, showcasing its active engagement in the market [2] - The company holds 65 trademark registrations and 302 patents, along with 71 administrative licenses, reflecting its commitment to innovation and compliance [2]